Fulgent Genetics, Inc.
FLGTNASDAQHealthcare● Active
$18.68
$-0.47(-2.45%)
Market Cap$530523638
P/E Ratio—
52W High$31.04
52W Low$13.46
Fulgent Genetics, Inc. (FLGT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FLGT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 1, 2026EPS Actual
-$0.36
Est. -$0.35 · -3.4%
Revenue
$0.07B
Est. $0.07B · +4.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 1, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
FLGT reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 31, 2026 | -$0.46 | — | — | — | $0.09B | — |
| ▼ Q2 FY2026 | May 1, 2026 | -$0.35 | -$0.36 | -3.4% | $0.07B | $0.07B | +4.5% |
| ▲ Q1 FY2026 | Feb 27, 2026 | $0.03 | $0.16 | +433.3% | $0.08B | $0.09B | -2.4% |
| ▲ Q4 FY2025 | Nov 7, 2025 | -$0.24 | $0.14 | +158.3% | $0.08B | $0.09B | -1.5% |
| ▲ Q3 FY2025 | Aug 1, 2025 | -$0.23 | $0.07 | +130.4% | $0.08B | $0.08B | +0.5% |
| ▲ Q2 FY2025 | May 2, 2025 | -$0.19 | $0.04 | +121.0% | $0.07B | $0.08B | -4.6% |
| ▲ Q1 FY2025 | Feb 28, 2025 | -$0.31 | $0.04 | +112.9% | $0.08B | $0.08B | +1.1% |
| ▲ Q4 FY2024 | Nov 8, 2024 | -$0.19 | $0.31 | +263.2% | $0.07B | $0.08B | -4.8% |
Q3 FY2026
Jul 31, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 1, 2026Miss
EPS Actual
-$0.36
EPS Est.
-$0.35
EPS Surpr.
-3.4%
Revenue
$0.07B
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
$0.16
EPS Est.
$0.03
EPS Surpr.
+433.3%
Revenue
$0.08B
Q4 FY2025
Nov 7, 2025Beat
EPS Actual
$0.14
EPS Est.
-$0.24
EPS Surpr.
+158.3%
Revenue
$0.08B
Q3 FY2025
Aug 1, 2025Beat
EPS Actual
$0.07
EPS Est.
-$0.23
EPS Surpr.
+130.4%
Revenue
$0.08B
Q2 FY2025
May 2, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.19
EPS Surpr.
+121.0%
Revenue
$0.07B
Q1 FY2025
Feb 28, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.31
EPS Surpr.
+112.9%
Revenue
$0.08B
Q4 FY2024
Nov 8, 2024Beat
EPS Actual
$0.31
EPS Est.
-$0.19
EPS Surpr.
+263.2%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q3 FY2028 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q2 FY2028 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q1 FY2028 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q4 FY2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 1, 2026 | -3.4% | $15.19 | $14.13 | -6.98% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +433.3% | $24.76 | $15.33 | -38.09% |
| ▲ Q4 FY2025 | Nov 7, 2025 | +158.3% | $22.31 | $26.36 | +18.15% |
| ▲ Q3 FY2025 | Aug 1, 2025 | +130.4% | $17.18 | $18.53 | +7.86% |
| ▲ Q2 FY2025 | May 2, 2025 | +121.0% | $17.25 | $20.54 | +19.07% |
| ▲ Q1 FY2025 | Feb 28, 2025 | +112.9% | $15.69 | $15.45 | -1.53% |
| ▲ Q4 FY2024 | Nov 8, 2024 | +263.2% | $22.02 | $19.43 | -11.76% |
| ▲ Q3 FY2024 | Aug 2, 2024 | +148.4% | $23.57 | $25.06 | +6.32% |
Q2 FY2026-6.98%
Report Date
May 1, 2026
EPS Beat/Miss
-3.4%
Price Before
$15.19
Price After
$14.13
Q1 FY2026-38.09%
Report Date
Feb 27, 2026
EPS Beat/Miss
+433.3%
Price Before
$24.76
Price After
$15.33
Q4 FY2025+18.15%
Report Date
Nov 7, 2025
EPS Beat/Miss
+158.3%
Price Before
$22.31
Price After
$26.36
Q3 FY2025+7.86%
Report Date
Aug 1, 2025
EPS Beat/Miss
+130.4%
Price Before
$17.18
Price After
$18.53
Q2 FY2025+19.07%
Report Date
May 2, 2025
EPS Beat/Miss
+121.0%
Price Before
$17.25
Price After
$20.54
Q1 FY2025-1.53%
Report Date
Feb 28, 2025
EPS Beat/Miss
+112.9%
Price Before
$15.69
Price After
$15.45
Q4 FY2024-11.76%
Report Date
Nov 8, 2024
EPS Beat/Miss
+263.2%
Price Before
$22.02
Price After
$19.43
Q3 FY2024+6.32%
Report Date
Aug 2, 2024
EPS Beat/Miss
+148.4%
Price Before
$23.57
Price After
$25.06
Avg Beat Reaction+0.00%
Avg Miss Reaction-6.98%
Beat Rate7 / 8 quarters
Largest Move-38.09% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FLGT ends December
Fulgent Genetics, Inc. (FLGT) most recently reported earnings on May 1, 2026 for Q2 FY2026, posting EPS of $-0.36 — missing the analyst consensus of $-0.35 by -3.4%. The next FLGT earnings date is expected around September 1, 2026.
Each quarter, investors track FLGT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FLGT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FLGT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FLGT earnings · 5 questionsFulgent Genetics, Inc.'s next earnings report is expected around September 1, 2026. FLGT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FLGT historically reports after market close (AMC).
FLGT earnings datewhen is FLGT earningsFLGT next earnings datewhen does FLGT report earningsFLGT earnings calendar
▸ Source: FMP · Fulgent Genetics, Inc. SEC filings · US GAAP · Fulgent Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026